C. Diff

Independent University Study Validates Indigo-Clean® Kills SARS-CoV-2, Influenza-A

Retrieved on: 
Wednesday, October 20, 2021
Euronext Paris, University, Atmosphere, Icahn School of Medicine at Mount Sinai, Buy American Act, School, MRSA, UT, Technology, COVID-19, ISIN, Transport, Growth, CAC 40, Severe acute respiratory syndrome coronavirus 2, MT, ESG, Research, Adequate Public Facilities Ordinance, Safety, University of Texas Health Science Center at Houston, Hospital, Patient, Group, Eyeish, Infection, Solution, CAC, Mount Sinai, C. Diff, Pharmaceutical industry

Indigo-Clean has become North America's most trusted visible light disinfection technology in hospitals, clinics, schools and public facilities, recently reaching its 500th installation. "The findings from the original research, and the validation from UT are critically important as the COVID-19 pandemic continues and flu season approaches," said Cliff Yahnke, Ph.D., Chief Scientist and Head of Clinical Affairs at Kenall. "Indigo-Clean has already proven it kills harmful bacteria, including C. Diff and staph such as MRSA, and reduces healthcare acquired infections (HAIs). Now we can add a scientifically proven SARS-CoV-2i virucidal efficacy claim of 94% to our value proposition. Indigo-Clean can easily be incorporated into any healthcare system's mitigation strategy – even as a lighting retrofit -- to help prevent infections, leading to better health outcomes for patients and offering a return on investment in as little as 2.2 months," he concluded.

Key Points: 
  • Today, Kenall announced that the University of Tennessee (UT) Health Science Center, a BSL-3 Regional Biocontainment Laboratory, has successfully provided independent confirmation of the ground-breaking research performed by Mt.
  • UT performed the study using identical test equipment and procedures at a single exposure level on the same type of luminaire.
  • The exposure level was chosen to minimize statistical variation and ensure proper comparison with the work performed at Mt.
  • "Indigo-Clean has already proven it kills harmful bacteria, including C. Diff and staph such as MRSA, and reduces healthcare acquired infections (HAIs).

First Light Diagnostics Receives FDA Clearance for its Rapid Clostridiodes difficile Test on the MultiPath® Analyzer

Retrieved on: 
Tuesday, July 20, 2021
Medical specialties, Diarrhea, Clinical medicine, Clostridioides difficile infection, Health care, Clostridioides difficile, C. Diff, Infection

The company announced today that the US Food and Drug Administration (FDA) has cleared its SensiTox C. difficile Toxin Test along with its proprietary MultiPath Analyzer to be marketed in the US.

Key Points: 
  • The company announced today that the US Food and Drug Administration (FDA) has cleared its SensiTox C. difficile Toxin Test along with its proprietary MultiPath Analyzer to be marketed in the US.
  • Each year, approximately 250,000 C. difficile infections and 12,500 deaths cost the US healthcare system about $1B.
  • Currently, both nucleic acid amplification tests and enzyme immunoassays are used to diagnose C. difficile infections.
  • First Light aims to improve diagnosis of C. difficile by commercializing an accurate test that is both sensitive and specific.

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

Retrieved on: 
Friday, May 21, 2021
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clostridioides difficile infection, Diarrhea, Clostridioides difficile, Microbiology, C. Diff, Clinical medicine, Draft:Roger J. Pomerantz, M.D.

b'Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI).

Key Points: 
  • b'Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI).
  • SER-109 resulted in a 26% absolute reduction of recurrence of CDI compared to placebo at 24 weeks post-treatment.
  • Seres is currently conducting an ongoing open-label study of SER-109 in patients with rCDI ( ClinicalTrials.gov identifier: NCT03183141), with full enrollment anticipated in Q3 2021.
  • The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.

Summit Therapeutics Publishes Scientific Updates to Corporate Website

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Clinical medicine, Gastroenterology, Diarrhea, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Feces, C. Diff

\xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.

Key Points: 
  • \xc2\xa0It also describes how ridinilazole has, thus far, shown a significant relative sparing of the microbiome compared to the broad-spectrum antibiotics that are the current standard of care for C. diff.
  • infection.\nClostridioides difficile, or C. difficile, infection (CDI) is a bacterial infection of the colon that produces toxins causing inflammation of the colon and severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration.
  • Accordingly, readers should not place undue reliance on forward-looking statements or information.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.\n'

Peggy Lillis Foundation releases Care Guide for Patients with C. diff Infections

Retrieved on: 
Friday, March 26, 2021
Diarrhea, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, C. Diff, Microbiology, Infection, Clinical medicine

BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."

Key Points: 
  • BROOKLYN, N.Y., March 26, 2021 /PRNewswire-PRWeb/ -- Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) today announced the online publication of its new "C. diff Care Guide."
  • The Care Guide provides patients with C. difficile infections and their caregivers wide-ranging information about the disease, its treatment and its long-term impacts in accessible language.
  • The Guide includes easy to understand information on topics C. diff patients frequently ask about, including how C. diff is spread, getting an accurate diagnosis, treatment options for primary and recurrent C. diff, preventing C. diff spread in the home, and socio-emotional impacts of recurrent C. diff.
  • About Peggy Lillis Foundation for C. diff Education & Advocacy
    Founded in response to the April 2010 death of 56-year-old kindergarten teacher, Peggy Lillis Foundation for C. diff Education & Advocacy (PLF) is the leading national organization dedicated to combating C. difficile infections through educating the public, empowering advocates and shaping policy.

Versatope Awarded Grant for a Novel C. diff Vaccine

Retrieved on: 
Wednesday, September 9, 2020
Medical specialties, Clinical medicine, Medicine, RTT, Waterborne diseases, Clostridioides difficile infection, Colitis, Vaccine, Diarrhea, C. Diff

C. diff is a bacterium that causes diarrhea and colitis (an inflammation of the colon).

Key Points: 
  • C. diff is a bacterium that causes diarrhea and colitis (an inflammation of the colon).
  • Approximately 1 in 11 infected people over the age of 65 die of the C. diff infection, or 15,000 people per year.
  • The NIAID grant will support Versatope's goal of producing a C. diff vaccine designed to protect against recurring disease by using exosome-like bacterial vesicles.
  • "The support from NIAID will enable Versatope to apply its bioinformatic and structure-based vaccine approach to new bacterial infection targets and deliver novel C. diff vaccine candidates," said Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc.
    "We are proud to have Versatope as an M2D2 resident company.

Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference

Retrieved on: 
Tuesday, June 2, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Medical specialties, Clostridioides difficile infection, Diarrhea, RTT, Clostridioides difficile, C. Diff, Medicine, Microbiology, Breakthrough therapy, David Berry

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 9th at 2:10 p.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 9th at 2:10 p.m.
  • A live audio webcast of the presentation will be available under the Investors and Media section of Seres website.
  • A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
  • Seres SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection.

BioHiTech Enters Into Agreement to Distribute Altapure High-Level Disinfectant Technology That Can Effectively Kill Bacteria, Fungus, C.Difficile Spores, and Viruses Such as Coronavirus 2 (SARS-CoV-2)

Retrieved on: 
Tuesday, June 2, 2020
Bacteria, Microorganisms, Clostridiaceae, Gram-positive bacteria, Microbiology, C. Diff, Clostridioides difficile, Diarrhea, Clostridium difficile, Disinfectant, Clostridium

We look forward to working together with the team at Altapure to begin to pursue opportunities to help our customers thrive with a new eye towards safety as our country and the rest of the world begins to reopen for business."

Key Points: 
  • We look forward to working together with the team at Altapure to begin to pursue opportunities to help our customers thrive with a new eye towards safety as our country and the rest of the world begins to reopen for business."
  • auris and Clostridium difficile (C. difficile).
  • Altapure is committed to providing its customers with the highest quality products and processes in the marketplace that are safe to use and are environmentally friendly.
  • All of Altapure's products are engineered, manufactured, and assembled in the U.S.
    "We are excited to establish this relationship with BioHiTech to expand the distribution reach of our state-of-the-art high-level disinfection technologies," said Carl L. Ricciardi, co-founder and CEO of Altapure.

Seres Therapeutics to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 28, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Clostridioides difficile infection, Diarrhea, RTT, Clostridioides difficile, C. Diff, Medicine, Microbiology, Breakthrough therapy, David Berry

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m.
  • A live audio webcast of the presentation will be available under the Investors and Media section of Seres website.
  • Seres SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection.
  • Seres SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection.

Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma

Retrieved on: 
Thursday, February 6, 2020
Bacteria, Medical specialties, Microbiology, Antibiotics, Pyridines, Diarrhea, Bacteriology, Microbiomes, Clostridioides difficile, Ridinilazole, Human gastrointestinal microbiota, C. Diff

Oxford, UK, and Cambridge, MA, US, 6 February 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratrios SA (Eurofarma).

Key Points: 
  • Oxford, UK, and Cambridge, MA, US, 6 February 2020 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratrios SA (Eurofarma).
  • The $1.0 million milestone payment was triggered by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection (CDI).
  • CDI is a global issue caused largely by broad spectrum antibiotic-induced imbalances in the healthy gut microbiome.
  • Eurofarma is an ideal partner for us with the necessary expertise to successfully market ridinilazole in Latin America, should it receive approval.